Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SYR-472 25 mg and 50 mg tablets in healthy Japanese male adults
jRCT2080222761Phase 1
- Sponsor
- Takeda
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Primary pharmacokinetic bioequivalence parameters.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222761.